The abstract is read at the publisher; the summary is JClub's.
Nirsevimab is linked to 78.1% adjusted effectiveness against RSV-associated hospitalizations in U.S. children 8–23 months at high risk during their second RSV season.
- Why it matters: Second-season nirsevimab eligibility is limited, making real-world effectiveness estimates important for guiding prevention in high-risk young children.
- What they did: In a retrospective test-negative case-control study across 26 hospitals in 24 U.S. states during 2024–2025 and 2025–2026, 106 RSV-positive cases and 125 RSV-negative controls were analyzed with multivariable logistic regression.
- The result: Adjusted effectiveness was 78.1% (95% CI, 55.2%–89.3%), with a median 66.5 days from receipt to symptom onset; effectiveness was higher at 88.5% (95% CI, 63.4%–96.4%) when given 8–59 days before symptoms.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.